Advisory Services Network LLC Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Advisory Services Network LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) by 29.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,384 shares of the medical device company’s stock after buying an additional 771 shares during the quarter. Advisory Services Network LLC’s holdings in DexCom were worth $1,733,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. American National Bank lifted its position in shares of DexCom by 33.8% during the first quarter. American National Bank now owns 91 shares of the medical device company’s stock worth $47,000 after purchasing an additional 23 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its position in shares of DexCom by 1.8% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,384 shares of the medical device company’s stock worth $743,000 after purchasing an additional 25 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of DexCom by 27.0% during the fourth quarter. Parkside Financial Bank & Trust now owns 141 shares of the medical device company’s stock worth $75,000 after purchasing an additional 30 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of DexCom by 2.9% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 1,120 shares of the medical device company’s stock worth $573,000 after purchasing an additional 32 shares in the last quarter. Finally, Bouvel Investment Partners LLC lifted its position in shares of DexCom by 0.9% during the first quarter. Bouvel Investment Partners LLC now owns 3,564 shares of the medical device company’s stock worth $1,823,000 after purchasing an additional 33 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Insider Transactions at DexCom

In related news, Director Steven Robert Pacelli sold 1,000 shares of DexCom stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total value of $72,550.00. Following the transaction, the director now directly owns 139,700 shares in the company, valued at approximately $10,135,235. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 3,000 shares of company stock worth $239,830. Insiders own 0.41% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $90.09 on Monday. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87. The firm has a market cap of $35.37 billion, a PE ratio of 187.69, a price-to-earnings-growth ratio of 3.64 and a beta of 1.03. The company’s 50 day simple moving average is $85.55 and its 200-day simple moving average is $91.86. DexCom, Inc. has a 12-month low of $66.89 and a 12-month high of $164.86.

DexCom (NASDAQ:DXCMGet Rating) last announced its earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The business had revenue of $696.20 million for the quarter, compared to analysts’ expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The business’s revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business posted $0.19 earnings per share. As a group, equities analysts predict that DexCom, Inc. will post 0.79 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DXCM. BTIG Research reduced their price target on shares of DexCom from $135.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Citigroup reduced their target price on shares of DexCom from $105.00 to $100.00 in a report on Friday, July 29th. Piper Sandler reduced their target price on shares of DexCom from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Sanford C. Bernstein began coverage on shares of DexCom in a report on Friday, July 15th. They issued an “outperform” rating and a $105.00 target price on the stock. Finally, Cowen reaffirmed a “buy” rating and issued a $85.00 target price on shares of DexCom in a report on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $115.23.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.